Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

250 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Intraperitoneal recombinant gamma-interferon in patients with recurrent ascitic ovarian carcinoma: modulation of cytotoxicity and cytokine production in tumor-associated effectors and of major histocompatibility antigen expression on tumor cells.
Allavena P, Peccatori F, Maggioni D, Erroi A, Sironi M, Colombo N, Lissoni A, Galazka A, Meiers W, Mangioni C, et al. Allavena P, et al. Among authors: galazka a. Cancer Res. 1990 Nov 15;50(22):7318-23. Cancer Res. 1990. PMID: 2121337 Clinical Trial.
Differences between in vivo and in vitro activation of cancer patient lymphocytes by recombinant interleukin 2: possible role for lymphokine-activated killer cell infusion in the in vivo-induced activation.
Gambacorti-Passerini C, Rivoltini L, Radrizzani M, Belli F, Sciorelli G, Ravagnani F, Galazka AR, Cascinelli N, Parmiani G. Gambacorti-Passerini C, et al. Among authors: galazka ar. Cancer Res. 1989 Sep 15;49(18):5230-4. Cancer Res. 1989. PMID: 2788498
Interferon for treatment.
Galazka A, Scott E. Galazka A, et al. BMJ. 1988 Aug 20-27;297(6647):558-9. doi: 10.1136/bmj.297.6647.558-b. BMJ. 1988. PMID: 3139203 Free PMC article. Clinical Trial. No abstract available.
Clinical and immunopathological results of a phase II study of perilymphatically injected recombinant interleukin-2 in locally far advanced, nonpretreated head and neck squamous cell carcinoma.
Mattijssen V, De Mulder PH, Schornagel JH, Verweij J, Van den Broek P, Galazka A, Roy S, Ruiter DJ. Mattijssen V, et al. Among authors: galazka a. J Immunother (1991). 1991 Feb;10(1):63-8. doi: 10.1097/00002371-199102000-00009. J Immunother (1991). 1991. PMID: 2012800
250 results